WO2016068615A1 - 염지하수 또는 해양심층수로부터 제조된 고경도의 미네랄 워터를 포함하는 혈압 감소 또는 이와 관련된 증상의 예방 또는 개선용 조성물 - Google Patents
염지하수 또는 해양심층수로부터 제조된 고경도의 미네랄 워터를 포함하는 혈압 감소 또는 이와 관련된 증상의 예방 또는 개선용 조성물 Download PDFInfo
- Publication number
- WO2016068615A1 WO2016068615A1 PCT/KR2015/011492 KR2015011492W WO2016068615A1 WO 2016068615 A1 WO2016068615 A1 WO 2016068615A1 KR 2015011492 W KR2015011492 W KR 2015011492W WO 2016068615 A1 WO2016068615 A1 WO 2016068615A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- water
- blood pressure
- composition
- mineral
- calcium
- Prior art date
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 144
- 230000036772 blood pressure Effects 0.000 title claims abstract description 96
- 239000011707 mineral Substances 0.000 title claims abstract description 90
- 229910052500 inorganic mineral Inorganic materials 0.000 title claims abstract description 89
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 208000024891 symptom Diseases 0.000 title claims abstract description 29
- 230000007423 decrease Effects 0.000 title claims abstract description 28
- 239000013535 sea water Substances 0.000 title claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 230000009467 reduction Effects 0.000 claims description 39
- 159000000007 calcium salts Chemical class 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 35
- 239000012141 concentrate Substances 0.000 claims description 30
- 239000011575 calcium Substances 0.000 claims description 21
- 239000013078 crystal Substances 0.000 claims description 21
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 19
- 239000011777 magnesium Substances 0.000 claims description 19
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 18
- 229910052791 calcium Inorganic materials 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 17
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 16
- 239000003463 adsorbent Substances 0.000 claims description 16
- 229910052749 magnesium Inorganic materials 0.000 claims description 16
- 239000011591 potassium Substances 0.000 claims description 16
- 229910052700 potassium Inorganic materials 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 13
- 208000002173 dizziness Diseases 0.000 claims description 10
- 239000003651 drinking water Substances 0.000 claims description 10
- 235000020188 drinking water Nutrition 0.000 claims description 10
- 206010042772 syncope Diseases 0.000 claims description 10
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 9
- 230000006872 improvement Effects 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 206010010774 Constipation Diseases 0.000 claims description 8
- 206010019233 Headaches Diseases 0.000 claims description 8
- 206010024264 Lethargy Diseases 0.000 claims description 8
- 206010028813 Nausea Diseases 0.000 claims description 8
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 8
- 206010003119 arrhythmia Diseases 0.000 claims description 8
- 230000006793 arrhythmia Effects 0.000 claims description 8
- 208000006218 bradycardia Diseases 0.000 claims description 8
- 230000036471 bradycardia Effects 0.000 claims description 8
- 231100000869 headache Toxicity 0.000 claims description 8
- 206010022437 insomnia Diseases 0.000 claims description 8
- 230000008693 nausea Effects 0.000 claims description 8
- 230000035939 shock Effects 0.000 claims description 8
- 208000016354 hearing loss disease Diseases 0.000 claims description 6
- 239000012510 hollow fiber Substances 0.000 claims description 6
- 239000012267 brine Substances 0.000 claims description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims description 5
- 239000011148 porous material Substances 0.000 claims description 4
- 238000011033 desalting Methods 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 3
- 231100000862 numbness Toxicity 0.000 claims description 3
- 241001122767 Theaceae Species 0.000 claims description 2
- 235000015897 energy drink Nutrition 0.000 claims description 2
- 239000010865 sewage Substances 0.000 claims description 2
- 235000011496 sports drink Nutrition 0.000 claims description 2
- 235000013616 tea Nutrition 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 14
- 239000012535 impurity Substances 0.000 description 9
- 208000001953 Hypotension Diseases 0.000 description 8
- 230000005484 gravity Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 150000001450 anions Chemical class 0.000 description 7
- 230000036543 hypotension Effects 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 6
- 230000035487 diastolic blood pressure Effects 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 238000001223 reverse osmosis Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 230000035488 systolic blood pressure Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- -1 chlorine ions Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010612 desalination reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 208000016621 Hearing disease Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010033546 Pallor Diseases 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000003673 groundwater Substances 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 208000030134 Aortic valvular disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000005951 Post-Exercise Hypotension Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000009956 central mechanism Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003044 randomized block design Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001575 sodium mineral Inorganic materials 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a composition for the prevention or improvement of symptoms related to blood pressure reduction or blood pressure reduction, including high hardness mineral water prepared from salt water or deep sea water as an active ingredient.
- Low blood pressure generally means that the blood pressure of the forearm artery is measured by a sphygmomanometer to be lower than normal (shrinkage blood pressure 120 mmHg, diastolic blood pressure 80 mmHg), and hypotension during or after exercise decreases systolic blood pressure during exercise compared to before exercise. Is in the range of about 20 mmHg or more, and as the blood pressure decreases, various prognosis and symptoms appear depending on the degree. However, the degree of blood pressure reduction characterized by hypotension may vary from person to person.
- Symptoms of a decrease in blood pressure include fainting, dizziness, headache, nausea, numbness, general lethargy, insomnia and bradycardia, constipation, skin paleness, temporary vision and hearing disorders, shock and arrhythmia
- the sudden decrease in blood pressure during and after exercise is accompanied by the phenomenon of trembling, extreme nervous breakdown, fainting with dizziness, and wheezing.
- 8 SBP / 9 DBP mmHg for healthy individuals without specific disease 14 SBP / 9 DBP mmHg for people with borderline hypertension, 10 SBP / 7 DBP for people with high blood pressure Reduction of the mmHg range is assessed as a positive effect of exercise.
- blood pressure increases temporarily ( ⁇ 5 minutes) at the beginning of exercise (including resistance and endurance), but there is a continuous decrease from 10 minutes after the exercise to the end of the exercise.
- an increase in dehydration may cause a rapid decrease in blood pressure. Sudden decrease in blood pressure during such exercise may be exposed to aortic valvular disorder or serious heart disease. Therefore, during exercise, it is necessary to closely examine whether the blood pressure decreases, and when hypotension occurs, various efforts should be accompanied to reduce the oxygen supply and prevent fainting.
- a decrease in blood pressure within an appropriate range should occur during exercise, and after the exercise ends, the decrease in blood pressure may be maintained for a long time (10-12 hours).
- the present inventors have tried to develop compositions that can prevent and improve blood pressure reduction, in particular, sudden blood pressure reduction during or after exercise.
- blood pressure was maintained at the normal blood pressure (120/80 mmHg) level, and general blood pressure reduction was By confirming that it is significantly smaller than the marathoner ingesting purified water, it was confirmed that the high hardness mineral water can be used for the prevention and improvement of blood pressure reduction and blood pressure reduction-related symptoms, and completed the present invention.
- Another object of the present invention is to provide a method for preventing or improving blood pressure reduction.
- Still another object of the present invention is to provide a composition for preventing or improving blood pressure reduction-related symptoms.
- Another object of the present invention is to provide a method for preventing or ameliorating blood pressure reduction-related symptoms.
- the present invention provides a composition for the prevention or improvement of blood pressure reduction comprising mineral water having a hardness value of 100-2000 prepared from salt water or deep sea water as an active ingredient.
- the present invention provides a blood pressure comprising administering to a subject in need thereof a composition comprising mineral water having a hardness value of 100-2000 prepared from salt water or deep sea water as an active ingredient. It provides a method of preventing or improving reduction.
- the present inventors have tried to develop compositions that can prevent and improve blood pressure reduction, in particular, sudden blood pressure reduction during or after exercise.
- blood pressure was maintained at the normal blood pressure (120/80 mmHg) level, and general blood pressure reduction was By confirming that it is significantly smaller than the marathoner ingesting purified water, it was confirmed that the high hardness mineral water can be used for the prevention and improvement of blood pressure reduction and blood pressure reduction-related symptoms.
- the term “reduce blood pressure” refers to a condition in which blood pressure is lower than normal blood pressure (about 120/80 mmHg, although there are differences among individuals), or dizziness, headache, fainting, nervous breakdown, whistling, nausea, dizziness, It means a state in which the blood pressure is lowered to a blood pressure level accompanied by symptoms such as generalized lethargy, temporary vision or hearing impairment, constipation, insomnia, bradycardia, skin paleness, shock or arrhythmia, and the like, which are caused by blood pressure reduction.
- prevention refers to preventing (suppressing) the drop of blood pressure below the normal blood pressure by the ingestion of the composition of the present invention, the width of the blood pressure decrease is reduced by the ingestion of the composition of the present invention (radical Prevention of blood pressure reduction), or by ingestion of the composition of the present invention means that the blood pressure falls to the blood pressure level accompanying the above symptoms
- improvement means raising the blood pressure to the normal blood pressure level, It means to return the blood pressure to a level at which the symptoms accompanying the blood pressure reduction, such as, or to reduce the frequency or intensity of occurrence of the symptoms accompanying the blood pressure reduction.
- the decrease in blood pressure is a decrease in blood pressure during or after exercise.
- the exercise is an aerobic exercise that lasts for 10 minutes or more, and such aerobic exercise includes soccer, basketball, ball game, walking, running (for example, long distance running such as marathon, ultra marathon), cycling, climbing, swimming And treadmills.
- the term “reduction of blood pressure during or after exercise” refers to a condition in which systolic blood pressure is lowered by 14 mmHg or more during or after exercise, or dizziness, headache, fainting, nervousness, whistling, nausea, limbs and limbs. It refers to a state in which the blood pressure is lowered to the level of blood pressure accompanied by symptoms such as tingling, generalized lethargy, temporary vision or hearing impairment, constipation, insomnia, bradycardia, skin paleness, shock, or arrhythmia.
- the composition of the present invention prevents a sudden decrease in blood pressure (constrictor or diastolic blood pressure). That is, the composition of the present invention alleviates the width at which blood pressure is reduced. In one example, this sudden decrease in blood pressure is a decrease in blood pressure during or after exercise.
- salt water refers to raw water for use as a groundwater in a rock aquifer containing a certain amount of dissolved solids, such as salt, for the purpose of eating water in a natural state that can maintain the stability of water quality.
- Ocean deep water means water in the sea with a depth of more than 200 m, which is hardly reachable by sunlight.
- the high hardness mineral water contained as an active ingredient in the present invention can be prepared using salt water, and if the salt water is used, it can be used for the production of high hardness mineral water without limitation.
- high hardness mineral water can be prepared using groundwater in a rock aquifer with a total dissolved solids content of more than 2000 mg / l, such as salt dissolved in water.
- the term "hardness” refers to the Ca 2 +, Mg 2 +, such as 2, the strength as indicated in terms of CaCO 3, which occurs by a cationic metal ion, the corresponding value of water which is dissolved in water do.
- the hardness can be calculated by the following equation.
- Mineral water of the present invention has a hardness (mg / l as CaCO 3 ) of 100-2000.
- the mineral water of 100-2000 hardness may comprise 15-500 mg / l magnesium, 5-170 mg / l calcium and 4.5-150 mg / l potassium.
- Mineral water of the present invention may have various hardness values within the hardness range.
- the hardness of the mineral water is 100-1900, 100-1800, 100-1700, 100-1600, 100-1500, 100-1400, 100-1300, 100-1200, 100-1100 Or 100-1000;
- the hardness of the mineral water is 200-1900, 200-1800, 200-1700, 200-1600, 200-1500, 200-1400, 200-1300, 200-1200, 200-1100 or 200 -1000;
- the hardness of the mineral water is 300-1900, 300-1800, 300-1700, 300-1600, 300-1500, 300-1400, 300-1300, 300-1200, 300-1100 or 300-1000;
- the hardness of the mineral water is 400-1900, 400-1800, 400-1700, 400-1600, 400-1500, 400-1400, 400-1300, 400-1200, 400-1100 or 400-1000;
- the hardness of the mineral water is 500-1900, 500-1800
- the mineral water of hardness 100 includes magnesium: 15-25 mg / l, calcium: 5-8.5 mg / l, and potassium: 4.5-7.5 mg / l, and has a hardness of 300
- Mineral water contains magnesium: 45-75 mg / l, calcium: 15-25.5 mg / l, and potassium: 13.5-22.5 mg / l
- mineral water of hardness 700 includes magnesium: 105-175 mg / l, calcium : 35-59.5 mg / l, and potassium: 31.5-52.5 mg / l
- the hardness 1000 mineral water is magnesium: 150-250 mg / l, calcium: 50-85 mg / l, and potassium: 45- 75 mg / l (including magnesium per 100 hardness: 15-25 mg / l calcium: 5-8.5 mg / l and potassium: 4.5-7.5 mg / l).
- the composition of the invention is a mineral water of hardness 100-1200 comprising 15-300 mg / l magnesium, 5-102 mg / l calcium and 4.5-90 mg / l potassium It includes.
- the composition of the invention is a mineral water of hardness 200-1200 comprising 30-300 mg / l magnesium, 10-102 mg / l calcium and 9-90 mg / l potassium It includes.
- the composition of the invention is a mineral water of hardness 300-1200 comprising 45-300 mg / l magnesium, 15-102 mg / l calcium and 13.5-90 mg / l potassium It includes.
- the composition of the invention is a mineral of hardness 400-1200 comprising 60-300 mg / l magnesium, 20-102 mg / l calcium and 18-90 mg / l potassium Contains water.
- the composition of the present invention has a hardness of 500-1200 comprising 75-300 mg / l magnesium, 25-102 mg / l calcium and 22.5-90 mg / l potassium Contains mineral water.
- the composition of the present invention has a hardness of 600-1200 comprising 90-300 mg / l magnesium, 30-102 mg / l calcium and 27-90 mg / l potassium Contains mineral water.
- the composition of the present invention can be prepared in various forms.
- the compositions of the present invention may be prepared in the form of drinking water, tea, sports drinks, ionic drinks or energy drinks.
- the composition of the present invention is prepared with drinking water can be easily ingested for the prevention and improvement of hypotension or hypotension-related symptoms, on the other hand, citric acid, liquid fructose, sugar, glucose, Additional minerals (eg, phosphates, iron, copper), various vitamins, acetic acid, malic acid, fruit juices, and / or various plant extracts (eg, plant extracts containing polyphenols) may be further included to prepare various drinks. .
- the mineral water of the present invention has high hardness and is characterized by containing a large amount of magnesium, calcium and potassium ions.
- the following problem occurs when preparing mineral water containing a large amount of the ions.
- the first problem is that when a large amount of mineral concentrate is added to the demineralized water in order to increase the mineral content of the drinking water, not only cations such as magnesium and potassium, but also sulfate ions and chlorine ions that reduce the eating sensation are contained in a large amount.
- the second problem is that when calcium salt separated from concentrated water is added to the demineralized water for the dissemination of calcium, the salt component and calcium carbonate added to the calcium salt are added, and the drinking water of drinking water is lowered, and the calcium salt has low solubility so that the actual calcium Dissemination efficiency is low. Therefore, the production of high hardness mineral water is not easy due to the above problems.
- the composition of the present invention is a mineral concentrate obtained by separating calcium salt crystals and salts from demineralized water obtained by desalting brine or deep sea water from (i) demineralized sewage or deep sea water, and (ii) It may include a mineral water having a hardness of 100-2000 prepared by mixing the calcium salt obtained by removing the calcium carbonate and the salt attached to the calcium salt crystals from the calcium salt crystals separated from the concentrated water.
- the desalting treatment for separating demineralized water and concentrated water from brine or deep sea water can be carried out by applying any technique known in the art.
- Techniques for the desalination treatment include evaporation, seawater freezing, reverse osmosis, ion exchange resin and electrodialysis.
- the desalination treatment passes raw water through the reverse osmosis membrane to separate the concentrated water including the ionic component and the demineralized water from which the ionic component is removed.
- the raw water may be used after undergoing a pretreatment process such as filtration to remove suspended solids.
- the pretreatment process is to remove impurities that may cause clogging during reverse osmosis filtration and may be subjected to conventional microfiltration or ultrafiltration.
- the demineralized water obtained from the raw water may be obtained by two or more desalination treatments.
- raw water may be passed through a first reverse osmosis membrane to obtain first concentrated water and first demineralized water
- second concentrated water and second demineralized water may be obtained by passing the first demineralized water through a second reverse osmosis membrane.
- the calcium salt and the mineral concentrate separated from the first concentrated water may be added to the second demineralized water to prepare high hardness mineral water.
- the concentrated water contains a large amount of calcium salts such as calcium carbonate, calcium sulfate and calcium chloride, sodium chloride, and minerals.
- the calcium salt and salt are separated stepwise from the concentrated water separated from the raw water.
- the separation of the calcium salt and salt is concentrated water to have an appropriate specific gravity value (density ratio of the concentrated water to the density of the water at the same temperature and pressure) so that the calcium salt crystal and salt in the concentrated water can be precipitated It may be carried out by separating the calcium salt crystals and salt which is precipitated by heating and concentration.
- the calcium salt is separated by separating the precipitated calcium salt crystals by heating and concentrating the concentrated water so that the specific gravity (density ratio of the concentrated water to the density of the water under the same temperature and pressure) is 1.11 or more. can do.
- the preferred specific gravity of the concentrated water for the separation of calcium salt is 1.11-1.23. Separation of the calcium salt may use a mesh network, preferably 300-350 mesh, more preferably 300 mesh can be separated.
- the first precipitated calcium salt crystals are separated, and the filtrate is heated and concentrated to have a specific gravity of 1.19-1.23. This can be done by removing.
- the separation of the salt may be carried out by separating the precipitated salt by heating and concentrating the concentrated water so that the specific gravity is 1.24 or more.
- the preferred specific gravity of the concentrated water for the separation of salts is 1.24-1.32. Since the mineral concentrate (liquid) and salt (solid) are present together in the heated concentrated water, the salt may be separated by centrifugation or by using a dehydrator. The separated salt can be further refined into mineral salts.
- the heating of the concentrated water may be performed slowly with stirring.
- the calcium salt and the salt-free concentrated water may be further heated and concentrated to concentrate the mineral component.
- the mineral concentrate in which the potassium salt and the salt component mixed in the demineralized water is removed (a) filtering the mineral concentrate with a filter having a physical adsorbent; (b) refiltering the filtered mineral concentrate with a filter having a physical adsorbent; And (c) filtering the mineral concentrate filtered in step (b) with a hollow fiber membrane filter having a plurality of pores, thereby removing anions and impurities. Removal of impurities is an essential process for drinking water production, and removal of negative ions is a process required to improve the refreshing feel of mineral water.
- the process is characterized by filtering the mineral concentrate with a filter having a physical adsorbent and then refiltering the filtered mineral concentrate with a filter having a physical adsorbent.
- Filters used for filtering and refiltering can reuse the same filter or use separate filters.
- a filter having a difference in the length of filter, the component, the type of adsorbent, and / or the size of the micropore of the adsorbent may be used.
- anions particularly chlorine ions and sulfate ions
- impurities particularly silt
- Re-filtering by the filter maximizes the removal efficiency of negative ions and impurities (primary filtering).
- the first filtered mineral concentrated water is secondarily filtered by the hollow fiber membrane filter to further improve anion and impurities removal efficiency (secondary filtering).
- a filter having a physical adsorbent capable of adsorbing impurities and anions in a solution can be used without limitation.
- the physical adsorbent is activated carbon, diatomaceous earth, zeolite, silica gel, starch, bentonide or alumina, more preferably activated carbon.
- an appropriate activated carbon filter may be selected and used according to the amount of mineral concentrate to be filtered. For example, when processing 100 L of mineral concentrate, it is preferable to use 8-12 inch activated carbon filter, and when processing 200 L of mineral concentrate, it is preferable to use 18-22 inch activated carbon filter. More preferably, 10-inch activated carbon filter is used when processing 100 L of mineral concentrate, and 20-inch activated carbon filter is used when processing 200 L of mineral concentrate.
- the concentrated water filtered first by a filter having a physical adsorbent is secondly filtered with a hollow fiber membrane to further filter out impurities including microorganisms and silts and anions, and to pass mineral components in the concentrate.
- the hollow fiber membrane filter may be used without limitation as long as it is a micro filter having a plurality of pores, and the pores are 0.01-0.5 ⁇ m in diameter, preferably 0.05-0.5 ⁇ m, and more preferably 0.1-0.5 ⁇ m.
- the hollow fiber membrane filter is a sterilization filter.
- the silt and anion in the mineral concentrate are removed by the filtering, preferably the silt, chlorine ions and sulfate ions are removed.
- the process of filtering the mineral concentrate by the filter having a physical adsorbent ⁇ refiltering by a filter having a physical adsorbent of the filtered concentrate ⁇ the refiltering of the refiltered concentrate may be repeated one or more times, preferably one or more times, more preferably 1-5 times, even more preferably 1-4 times.
- the mineral concentrate may be supplied to the filter at a suitable speed or a suitable flow rate by a supply means.
- the supply means uses a pump, more preferably a metering pump capable of transferring the mineral concentrate to the filter at a constant speed (or flow rate).
- the removal of salt and calcium carbonate from the calcium salt crystals separated from the concentrated water comprises: (i) a vessel comprising hot water equipped with a 300-350 mesh network of calcium salt crystals separated from the concentrated water; And calcium salt crystals not passed through the network. At this time, the salt attached to the calcium salt crystals are dissolved in hot water, and calcium carbonate passes through the mesh net and precipitates at the bottom of the container.
- Calcium salt crystals separated from the concentrated water inevitably contain the concentrated water because it is separated from the concentrated water containing a large amount of salt, and when added to demineralized water without removing it, The texture is degraded. In addition, due to the calcium carbonate deteriorates the eating of mineral water. Therefore, in the present invention, a purification process for removing the salt (concentrated water) and calcium carbonate attached to the calcium salt crystal is performed.
- step (i) after the calcium salt crystals are added, the container is slowly shaken.
- the mesh network of step (i) uses a mesh of the same standard or higher than that used when extracting calcium salt crystals, preferably 300 mesh (1 inch) 300 holes) are used, more preferably 300 mesh.
- the temperature of the solution in the vessel is set to the temperature at which the calcium salt can precipitate into crystals (the calcium salt can be present as crystals). It is because when it is lower than the said temperature, calcium salt will melt
- the temperature can be set to 60-100 ° C, preferably 65-100 ° C, more preferably 70-100 ° C. This is to meet the same conditions because the temperature is extracted at 70-100 °C during the extraction of calcium salt.
- the calcium salt crystals separated in step (ii) can be dried and stored using natural drying, a dry oven and a microwave oven, and preferably dried using a dry oven or a microwave oven. Thereafter, the stored calcium salt may be added to the demineralized water for the dissemination of calcium.
- the term “individual” includes, without limitation, human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, monkey, chimpanzee, baboon or rhesus monkey. Specifically, the subject of the present invention is a human.
- the present invention comprises the above-mentioned composition as an active ingredient, dizziness, headache, fainting, whistling, nausea, hand and feet, general lethargy, temporary vision or hearing disorders, neurodebilitating, constipation It provides a composition for the prevention or amelioration of blood pressure reduction-related symptoms caused by blood pressure reduction selected from the group consisting of, insomnia, bradycardia, pale skin, shock and arrhythmia.
- the invention comprises the step of administering the above-described composition to a subject in need thereof, dizziness, headache, fainting, whistling, nausea, palpitations, systemic lethargy, temporary vision or
- a method of preventing or ameliorating blood pressure reduction-related symptoms caused by a decrease in blood pressure selected from the group consisting of hearing impairment, nervous breakdown, constipation, insomnia, bradycardia, skin paleness, shock and arrhythmia is provided.
- composition for preventing or improving the blood pressure reduction-related symptoms includes the composition for preventing or improving blood pressure reduction as an active ingredient, common content between the two is to avoid excessive complexity of the present specification according to the repetitive description. The description is omitted.
- high hardness mineral water prepared from the salt water or the deep sea water described above has the effect of preventing the drop of blood pressure or reducing the degree to which the blood pressure drops. Can be prevented or improved.
- the ingestion of the composition of the present invention may prevent the occurrence of symptoms as described above by reducing blood pressure during or after exercise, or may reduce the number and intensity of occurrence of the symptoms, and in another example, may occur according to orthostatic hypotension. It is possible to prevent the occurrence of such symptoms, or to reduce the number and intensity of symptoms.
- the present invention relates to a composition for the prevention or improvement of the symptoms associated with blood pressure reduction or blood pressure reduction comprising high hardness mineral water prepared from salt water or deep sea water as an active ingredient.
- high hardness mineral water prepared from salt water or deep sea water in particular, has an effect of preventing sudden drop of blood pressure during exercise or after exercise, or alleviating the degree of drop of blood pressure, It can be used for the prevention and amelioration of symptoms related to sudden blood pressure reduction during and after exercise.
- Figure 1 shows the systolic blood pressure changes of the active group and the control group (control group).
- Figure 2 shows the change in diastolic blood pressure of the active group and the control group (control group).
- the specific experimental method was as follows. Of the participants in the 100 km Ultra Marathon, 23 controls and 30 experimental groups were selected in advance. The experimental group and the control group were identified by wearing different color LED bands (belt-on LED band, Hyunwoo International Co., Ltd.) on the wrist. As drinking water, normal purified water (hardness 30) was supplied to the control group, and mineral water (Aribio Co., Ltd.) having a hardness of 700 was supplied to the experimental group. Thirty experimental groups were supplemented with mineral water with a hardness of 700 for each water support section.
- blood pressures of systolic and diastolic were measured using a mercury blood pressure monitor (Spirit, Chinkou Medical Instrument, Taiwan) at 50 km and 100 km (total 3 times).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Tea And Coffee (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
Description
Claims (10)
- 염지하수 또는 해양심층수로부터 제조된 경도 값이 100-2000인 미네랄 워터를 유효성분으로 포함하는 혈압 감소의 예방 또는 개선용 조성물.
- 제 1 항에 있어서, 상기 미네랄 워터는 15-500 mg/ℓ의 마그네슘, 5-170 mg/ℓ의 칼슘 및 4.5-150 mg/ℓ의 칼륨을 포함하는 것을 특징으로 하는 조성물.
- 제 1 항에 있어서, 상기 미네랄 워터는 경도 값이 100-1200인 것을 특징으로 하는 조성물.
- 제 3 항에 있어서, 상기 미네랄 워터는 15-300 mg/ℓ의 마그네슘, 5-102 mg/ℓ의 칼슘 및 4.5-90 mg/ℓ의 칼륨을 포함하는 것을 특징으로 하는 조성물.
- 제 1 항에 있어서, 상기 혈압 감소는 운동 중 또는 운동 후의 혈압 감소인 것을 특징으로 하는 조성물.
- 제 1 항에 있어서, 상기 조성물은 음용수, 차, 스포츠 드링크, 이온 음료 또는 에너지 드링크인 것을 특징으로 하는 조성물.
- 제 1 항에 있어서, 상기 미네랄 워터는 염지하수 또는 해양심층수를 탈염처리 하여 얻은 탈염수에 (i) 염지하수 또는 해양심층수를 탈염처리 하여 얻은 농축수로부터 칼슘염 결정 및 소금을 분리하여 얻은 미네랄 농축액 및 (ii) 상기 농축수로부터 분리된 칼슘염 결정으로부터 칼슘염 결정에 붙어있는 소금과 탄산칼슘을 제거하여 얻은 칼슘염을 혼합하여 100-2000의 경도로 제조되며, 이때 상기 미네랄 농축액은 물리 흡착제를 갖는 필터로 필터링하고, 필터링 된 미네랄 농축액을 물리 흡착제를 갖는 필터로 재필터링한 후, 재필터링 된 미네랄 농축액을 다수의 공극을 갖는 중공사막 필터로 필터링하여 얻은 것을 특징으로 하는 조성물.
- 제 1 항 내지 제 7 항 중 어느 한 항의 조성물을 유효성분으로 포함하는, 현기증, 두통, 실신, 휘청거림, 메스꺼움, 손발저림, 전신 무기력, 일시적인 시력 또는 청력 장애, 신경쇄약, 변비, 불면, 서맥, 피부 창백, 쇼크 및 부정맥으로 구성된 군으로부터 선택된 혈압 감소에 의하여 유발되는 혈압 감소-관련 증상의 예방 또는 개선용 조성물.
- 염지하수 또는 해양심층수로부터 제조된 경도 값이 100-2000인 미네랄 워터를 유효성분으로 포함하는 조성물을 이를 필요로하는 개체에게 투여하는 단계를 포함하는 혈압 감소의 예방 또는 개선방법.
- 염지하수 또는 해양심층수로부터 제조된 경도 값이 100-2000인 미네랄 워터를 유효성분으로 포함하는 조성물을 이를 필요로하는 개체에게 투여하는 단계를 포함하는, 현기증, 두통, 실신, 휘청거림, 메스꺼움, 손발저림, 전신 무기력, 일시적인 시력 또는 청력 장애, 신경쇄약, 변비, 불면, 서맥, 피부 창백, 쇼크 및 부정맥으로 구성된 군으로부터 선택된 혈압 감소에 의하여 유발되는 혈압 감소-관련 증상의 예방 또는 개선방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201580071583.XA CN107106599A (zh) | 2014-10-29 | 2015-10-29 | 包含由盐地下水或海洋深层水制备的高硬度矿物质水的用于预防或改善血压降低或与此相关的症状的组合物 |
US15/523,204 US20170312311A1 (en) | 2014-10-29 | 2015-10-29 | Composition, containing high-hardness mineral water prepared from salty underground water or deep-sea water, for preventing or alleviating decrease in blood pressure or symptoms related thereto |
EP15854802.4A EP3213757A1 (en) | 2014-10-29 | 2015-10-29 | Composition, containing high-hardness mineral water prepared from salty underground water or deep-sea water, for preventing or alleviating decrease in blood pressure or symptoms related thereto |
JP2017523203A JP2017534625A (ja) | 2014-10-29 | 2015-10-29 | 塩地下水または海洋深層水から製造された高硬度のミネラルウォーターを含む血圧低下またはそれと関連した症状の予防または改善用組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2014-0148415 | 2014-10-29 | ||
KR1020140148415A KR20160052935A (ko) | 2014-10-29 | 2014-10-29 | 염지하수 또는 해양심층수로부터 제조된 고경도의 미네랄 워터를 포함하는 혈압 감소 또는 이와 관련된 증상의 예방 또는 개선용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016068615A1 true WO2016068615A1 (ko) | 2016-05-06 |
Family
ID=55857844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/011492 WO2016068615A1 (ko) | 2014-10-29 | 2015-10-29 | 염지하수 또는 해양심층수로부터 제조된 고경도의 미네랄 워터를 포함하는 혈압 감소 또는 이와 관련된 증상의 예방 또는 개선용 조성물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20170312311A1 (ko) |
EP (1) | EP3213757A1 (ko) |
JP (1) | JP2017534625A (ko) |
KR (1) | KR20160052935A (ko) |
CN (1) | CN107106599A (ko) |
WO (1) | WO2016068615A1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10647591B2 (en) * | 2016-08-26 | 2020-05-12 | Quality Pure Co., Ltd. | High-magnesium concentrated liquid |
US20200029600A1 (en) * | 2018-07-26 | 2020-01-30 | Livewell Collective, LLC | Method of manufacturing beverage within container |
CN111453831A (zh) * | 2020-05-11 | 2020-07-28 | 浙江养生堂天然药物研究所有限公司 | 一种改善睡眠质量的饮用水 |
KR102233425B1 (ko) | 2020-11-23 | 2021-03-30 | 주식회사 아리바이오 | 비만의 예방 또는 치료용 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003063969A (ja) * | 2001-08-24 | 2003-03-05 | Goshu Yakuhin Kk | 海洋深層水より分離したミネラル濃縮液を用いた機能性商品 |
JP2007166990A (ja) * | 2005-12-22 | 2007-07-05 | Hiromasa Ohashi | 海洋深層水の利用方法 |
KR20140010654A (ko) * | 2012-07-16 | 2014-01-27 | 주식회사 아리바이오 | 해양 심층수 또는 염지하수로부터 고경도의 미네랄 워터를 제조하는 방법 |
KR20140052389A (ko) * | 2012-10-24 | 2014-05-07 | 주식회사 아리바이오 | 해양 심층수 또는 염지하수로부터 제조된 고경도의 미네랄 워터를 포함하는 변비 예방, 개선 또는 치료용 조성물 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102652563B (zh) * | 2012-04-18 | 2013-12-11 | 中国海洋大学 | 一种含有海洋深层水的保健饮用液及其制备方法 |
-
2014
- 2014-10-29 KR KR1020140148415A patent/KR20160052935A/ko not_active Application Discontinuation
-
2015
- 2015-10-29 CN CN201580071583.XA patent/CN107106599A/zh active Pending
- 2015-10-29 WO PCT/KR2015/011492 patent/WO2016068615A1/ko active Application Filing
- 2015-10-29 US US15/523,204 patent/US20170312311A1/en not_active Abandoned
- 2015-10-29 JP JP2017523203A patent/JP2017534625A/ja not_active Withdrawn
- 2015-10-29 EP EP15854802.4A patent/EP3213757A1/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003063969A (ja) * | 2001-08-24 | 2003-03-05 | Goshu Yakuhin Kk | 海洋深層水より分離したミネラル濃縮液を用いた機能性商品 |
JP2007166990A (ja) * | 2005-12-22 | 2007-07-05 | Hiromasa Ohashi | 海洋深層水の利用方法 |
KR20140010654A (ko) * | 2012-07-16 | 2014-01-27 | 주식회사 아리바이오 | 해양 심층수 또는 염지하수로부터 고경도의 미네랄 워터를 제조하는 방법 |
KR20140052389A (ko) * | 2012-10-24 | 2014-05-07 | 주식회사 아리바이오 | 해양 심층수 또는 염지하수로부터 제조된 고경도의 미네랄 워터를 포함하는 변비 예방, 개선 또는 치료용 조성물 |
Non-Patent Citations (1)
Title |
---|
RYLANDER, R. ET AL.: "Mineral Water Intake Reduces Blood Pressure Among Subjects Low Urinary Magnesium and Calcium Levels", BMC PUBLIC HEALTH, vol. 4, no. 56, 2004, pages 1 - 5, XP021005309 * |
Also Published As
Publication number | Publication date |
---|---|
CN107106599A (zh) | 2017-08-29 |
EP3213757A1 (en) | 2017-09-06 |
KR20160052935A (ko) | 2016-05-13 |
JP2017534625A (ja) | 2017-11-24 |
US20170312311A1 (en) | 2017-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016068615A1 (ko) | 염지하수 또는 해양심층수로부터 제조된 고경도의 미네랄 워터를 포함하는 혈압 감소 또는 이와 관련된 증상의 예방 또는 개선용 조성물 | |
KR101813695B1 (ko) | 염지하수 또는 해양심층수로부터 제조된 고경도의 미네랄 워터를 포함하는 기능성 음료 | |
US20200187536A1 (en) | Table salts and the manufacturing methods and system | |
CN103803749A (zh) | 一种用于泡茶的弱碱性水的制备方法 | |
CN103271404A (zh) | 醒酒、保胃、护肝、防宿醉的饮料及其制备方法 | |
US20170165295A1 (en) | Composition for preventing, alleviating or treating constipation, containing high hardness mineral water prepared from deep ocean water or desalinated groundwater | |
DK200900672A (da) | System og fremgangsm de til frembringelse af en opläsning med lavt indhold af suspenderede faste stoffer samt anvendelser deraf. | |
MXPA05010455A (es) | Formacion mejorada de hidrato y desarrollo para la desalinizacion basada en hidrato, por medio de enriquecimiento del agua a ser tratada. | |
KR20140010654A (ko) | 해양 심층수 또는 염지하수로부터 고경도의 미네랄 워터를 제조하는 방법 | |
CN112568342A (zh) | 一种富含茶氨酸的益智健脑饮料配方及其生产工艺 | |
CN1653926A (zh) | 桂圆菊花茶饮料 | |
KR20200067660A (ko) | 염지하수 또는 해양심층수로부터 제조된 고경도의 미네랄 워터를 포함하는 기능성 음료 | |
CN106278954B (zh) | 一种提取胍丁胺的方法 | |
EP0339540A1 (de) | Verfahren zur Reduzierung des Kaliumgehaltes in Fruchtsäften,-Nektaren und-Getränken | |
CN107535781A (zh) | 一种含有淡化海水的运动饮料及其制备方法 | |
CN209136231U (zh) | 一种方便装拆维护的直饮水机 | |
CN106071613A (zh) | 一种含竹盐和阿拉伯糖的功能饮料 | |
KR940000046A (ko) | 생맥산(生脈散)과 전해질을 병용한 스포츠음료의 제조방법 | |
CN115414383A (zh) | 血液透析浓缩液及其制备方法 | |
CN103931771A (zh) | 一种香蕉饮料 | |
Yu et al. | Effect of Noni Fruit Pre-supplementation on Fatigue after Long-distance Running in Male Middle Aged Athletes: 886 Board# 202 June 1, 2: 00 PM-3: 30 PM | |
CN1059814C (zh) | 男性青少年用补脑健身的中药制剂 | |
CN201793512U (zh) | 一种5-羟基色氨酸的精制设备 | |
CN107260804A (zh) | 一种丹参水提液的絮凝除杂方法及其应用 | |
CN112262937A (zh) | 一种肉苁蓉复合饮料及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15854802 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017523203 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015854802 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15523204 Country of ref document: US |